ScholarIQanswers from OpenAlex & ORCID
Patricia LoRusso
ResearcherPublications, citations & collaboration network
Patricia LoRusso is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Patricia LoRusso have?
ScholarIQindexed works
Patricia LoRusso has 1,281 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Patricia LoRusso have?
ScholarIQcitation count
Patricia LoRusso has 35,063 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Patricia LoRusso?
ScholarIQh-index
Patricia LoRusso has an h-index of 87 in OpenAlex.
What is the i10-index of Patricia LoRusso?
ScholarIQi10-index
Patricia LoRusso has an i10-index of 391 in OpenAlex.
What is the ORCID of Patricia LoRusso?
ScholarIQorcid
The ORCID for Patricia LoRusso is on the source record.
What is the OpenAlex record for Patricia LoRusso?
ScholarIQopenalex
The OpenAlex for Patricia LoRusso is on the source record.
What are the most-cited papers on Patricia LoRusso?
ScholarIQmost cited works
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
Joseph McLaughlin, Gang Han, Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy S. Herbst, Patricia LoRusso, David L. Rimm
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, Fabrice André, Jean‐Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schüler, Ulka N. Vaishampayan, Howard A. Burris, Guangming Tian, Mario Campone, Zev A. Wainberg, Wan‐Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, François Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmañà, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Fernández Montés, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, Ronnie Shapira‐Frommer